33 results about "HUVEC Cells" patented technology

The invention belongs to the technical field of gene engineering, and particularly relates to PDRN, a gene engineering vector, a cell, a preparation method and application thereof. The polydeoxyribonucleotide (PDRN) provided by the invention comprises a nucleotide sequence as shown in SEQ ID NO. 1; 1 or a partial fragment containing a nucleotide sequence shown in SEQ ID NO. 1; 1 or a sequence having 80% or more of homology with the nucleotide sequence as shown in SEQ ID NO. 1. The PDRN provided by the invention can effectively reduce and inhibit the expression level of inflammatory factors TNF-alpha and IL-6 and increase the wound healing rate of HUVEC cells, and is concentration-dependent. The PDRN provided by the invention has a good application prospect in preparation of anti-inflammatory or healing-promoting products.

The invention relates to the field of natural medicinal chemistry, and discloses an efficient separation and preparation method of a compound theanine diglucoside TFG. Although TFG structures are reported, separation from tea leaves is not disclosed. According to the invention, an efficient separation and purification method is established for the first time, and TFG is accurately extracted and identified from tea leaves by combining an HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector) guided multi-stage column chromatography technology with nuclear magnetic resonance and mass spectrometry. Experiments prove that the TFG activates an antioxidant pathway, improves H2O2-induced HUVEC cell and HT22 cell damage, protects the vascular endothelial barrier function and neuronal activity, and is suitable for developing antioxidant drugs for treating Alzheimer's disease. Compared with the prior art, the invention fills the blank of separation of the tea-derived TFG, explores the new application of the tea-derived TFG in the field of cell protection, and provides a new thought for natural product development and functional food research.

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.

The application belongs to the technical field of cell culture, and particularly relates to umbilical cord blood-derived endothelial cell culture additives, an endothelial cell culture method and application. The umbilical cord blood-derived endothelial cell culture additives comprise activated platelet-rich plasma and at least one of miR-132 and miR-193b-3p high expression and miR-155 low expression exosomes. The application further provides an endothelial cell culture medium comprising the umbilical cord blood-derived endothelial cell culture additives, and the culture medium can significantly improve the growth state of HUVEC cells and effectively reduce or even avoid the vacuolization phenomenon in the culture process.

The invention belongs to the field of medicines, and particularly relates to an in-vitro evaluation model for promoting skin wound healing based on a VPA-Exo drug-loaded exosome as well as a construction method and application of the in-vitro evaluation model. The construction method of the in-vitro evaluation model for promoting skin wound healing comprises the following steps: S1, after passage of resuscitated HSF cells and HUVEC cells, taking HSF cells or HUVEC cell suspension in a logarithmic phase, inoculating the HSF cells or HUVEC cell suspension on a culture plate, and culturing on a real-time label-free cell analyzer for 20-28 hours; and S2, then adding VPA-EXO with the concentration of 12.5 mu g / mL-400 mu g / mL to act on the HSF cells or the HUVEC cells.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

The invention discloses schizophyllan, which has two components with molecular weights of 1.54 * 10 < 7 > Da and 1.85 * 10 < 4 > Da respectively, and consists of glucose, mannose, galactose and fucose, and the molar ratio of glucose to mannose to galactose to fucose is 86: 8: 5: 1. The schizophyllan is a heterogeneous polysaccharide with glucose as a main component, and can promote proliferation of HaCaT cells and HUVEC cells. Meanwhile, the schizophyllan can remarkably promote the healing speed of a full-thickness skin wound model mouse wound and has excellent effects in the aspects of epithelium reformation, granulation tissue formation and tissue remodeling, and when 4 mg / mL of schizophyllan is used for treating the mouse wound, the healing rate reaches 96.65%.

This application belongs to the field of biomaterials, specifically relating to an antibacterial polymeric derivative of F127 with terminal modification of acetyl bromide, its preparation method, and its application. This application obtains F127AcBr by terminal modification of polymeric F127 with acetyl bromide via an acylation reaction. Its good antibacterial effect and biocompatibility were verified in vitro using plate antibacterial assays against Staphylococcus aureus and Escherichia coli, as well as live / dead staining assays of L929 cells and HUVEC cells. This application optimized the concentration of F127AcBr and loaded it into an MS hydrogel system. Excellent biocompatibility was confirmed in a diabetic mouse wound model using HE staining of mouse organs. Immunofluorescence staining against Staphylococcus aureus further confirmed the good antibacterial activity of F127AcBr.

The application is suitable for the technical field of nanocluster preparation, and provides reversible control fluorescent gold nanoclusters and a preparation method thereof, which comprises the following steps: adding 4mM chloroauric acid solution 221µL into a CK solution with a concentration of 2mM 443µL after being fully dissolved, then adding 2M NaOH 14.7µL, adjusting the pH value of the solution to 13, immediately mixing, wrapping with tin paper, transferring to a shaking incubator for reaction for 10h, and obtaining H-AuNCs with bright red fluorescence. 60µM H-AuNCs are co-granted with HUVEC cells for 2h, and bright red fluorescence is formed in the cells, so that biological imaging can be realized. The powder obtained by drying the H-AuNCs is transferred into a dimethyl sulfoxide solution to obtain organic phase D-AuNCs with bright blue fluorescence. The application prepares CK-AuNCs with high fluorescence intensity, and can realize reversible adjustment of the fluorescence color.

The present invention relates to a pharmaceutical composition including an IL-32θ mutant for the prevention or treatment of inflammatory diseases and / or cancer and a use thereof. The interleukin-32θ mutant (IL-32θ mutant) of the present invention can inhibit inflammatory cytokines and chemokines, inflammatory mediators and the metastasis and proliferation of cancer through intracellular pathways, and can suppress the expression of Intracellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) in Human Umbilical Vein Endothelial Cells (HUVECs), and thus can be used for preventing and treating inflammatory diseases such as atherosclerosis through the inhibition of monocyte-endothelial cell adhesion. The mutant can also be utilized as a research material for various cancers and / or inflammatory diseases.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

The invention discloses a human primary verrucoid hemangioma endothelial cell model construction method, a medicine and application, human primary verrucoid hemangioma endothelial cells can be successfully obtained, and a solid foundation is laid for screening the medicine for treating human verrucoid hemangioma. The method comprises the following steps: (1) constructing HUVEC cells transfected with MAP3K3 lentivirus; (2) detecting the expression level of the MEKK3 protein through a Western Blot experiment; and (3) separating the human primary verrucoid hemangioma endothelial cells.

The invention belongs to the technical field of medicines, and particularly relates to application of calycosin in preparation of a medicine for resisting herpes virus infection and the medicine. It is found through a large number of studies that calycosin has a remarkable inhibiting effect on herpes viruses, and the IC50 of the calycosin for resisting KSHV viruses on HUVEC cells is 5.965 micrograms / mL; the IC50 (half maximal inhibitory concentration) of the anti-KSHV virus on an iSLK.219 cell is 3.984 [mu] g / mL; and the IC50 (half maximal inhibitory concentration) of the anti-KSHV virus on the BCBL-1 cell is 3.023 mu g / mL. The calycosin is a low-toxicity and high-efficiency anti-herpes virus substance, can be used for preparing drugs for resisting herpes viruses and preventing and treating diseases caused by the herpes viruses, provides a safe and effective natural drug with small toxic and side effects for clinical treatment of the herpes virus diseases, and has very high clinical application value.

The invention discloses nanoparticles with a targeting function as well as a preparation method and application thereof, and relates to the technical field of medicines. The nano-particle has a core-shell structure, the surface of the nano-particle is loaded with alkannin and derivatives thereof, and the outside of the shell layer is coupled with a nucleic acid aptamer. The prepared nanoparticles have excellent targeting property, have no toxic effect on HUVEC cells, have good biocompatibility, can inhibit proliferation of tumor cells and promote apoptosis of the tumor cells, and have excellent glutathione (GSH) response performance; the nanoparticles and the aptamer are coupled to deliver the shikonin and the derivative of the shikonin in a targeted manner, so that tumors can be accurately treated; the preparation method is simple, convenient and easy to operate, and a strategy is provided for development of high-efficiency and low-toxicity innovative targeted drugs and precise treatment of tumors.

The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and discloses efficient synthesis of a novel polycyclic aromatic hydrocarbon derivative 5, 9-di-tert-butyl-12-mesitylene naphtho indolizine phenothiazine and an anti-cancer application of the novel polycyclic aromatic hydrocarbon derivative 5, 9-di-tert-butyl-12-mesitylene naphtho indolizine phenothiazine. According to the compound, a mesitylene group is introduced for the first time on the basis of a naphthoindolizine phenothiazine skeleton. The synthesis conditions are mild, and the yield is as high as 91%. In-vitro anti-cancer activity research shows that the compound has remarkable broad-spectrum anti-cancer activity and shows strong proliferation inhibition on human cervical cancer Hela cells (IC50 = 1.6 mu M), human lung cancer A549 cells (IC50 = 13.29 mu M) and human prostatic cancer PC-3 cells (IC50 = 19.1 mu M). Particularly, the activity on Hela cells is obviously superior to that of a clinical first-line drug cis-platinum. Preliminary toxicity evaluation shows that the toxicity of the compound to human normal umbilical vein endothelial cells (HUVEC) is far lower than that of cancer cells, and the selectivity is good.

The invention discloses a 2 '-alpha-ethynyl-beta-fluoronucleoside compound which has a structure as shown in a formula I, and pharmaceutically acceptable salts or various optical isomers, solvates or prodrugs thereof, and is a compound targeting a new structure of RNA (Ribonucleic Acid) virus polymerase. The invention also discloses a preparation method of the compound, a composition containing the compound and application of the compound in preparation of drugs for treating virus infection diseases. The 2 '-alpha-ethynyl-beta-fluoronucleoside compound obtained by the invention shows a remarkable chain termination intervention effect in a CCHFV polymerase system, an SARS-CoV-2 polymerase system and an EV71 polymerase system. The result of a cellular level inhibition experiment shows that the 2 '-alpha-ethynyl-beta-fluoronucleoside compound has an obvious inhibition effect on CCHFV on an HUVEC cell.

The invention relates to controllably degradable silicified DNA hydrogel and a preparation method and application thereof, the hydrogel is assembled into a three-dimensional network through a DNA structure with a single-chain region in the center and a linear DNA structure, and the mechanical property and thermal stability of the hydrogel are improved through in-situ silicification. The precisely designed single-chain region can still be recognized and degraded by specific nuclease after silicification, so that precisely controlled selective degradation is realized. The material takes human umbilical vein endothelial cells as an example, good biocompatibility of the material is verified, and the material can be used for cell embedding and releasing and is suitable for research and application fields of advanced biological materials, medicine, pharmacy and the like, such as organoid culture, tissue engineering, controllable drug release and the like.

The present application belongs to the technical field of bioengineering, and particularly relates to a tuna fish bone antioxidant oligopeptide and a preparation method thereof.The tuna fish bone antioxidant oligopeptide has good scavenging activity, and has good thermal stability and digestion resistance; the mechanism of action is to promote the release of nitric oxide (NO), improve the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), catalase (CAT) and total antioxidant capacity (T-AOC), and reduce the levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH); JQYG-1 can protect HUVEC cells from oxidative damage induced by hydrogen peroxide; JQYG-1 can exert an antioxidant effect and protect vascular endothelial cells, and can provide a candidate drug for the prevention and treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, cerebral thrombosis, myocardial infarction, atherosclerosis and heart failure.

The invention belongs to the technical field of medicines, and relates to a 3-benzylamino coumarin compound and application thereof. Experimental results show that the compound provided by the invention can significantly increase the survival rate of HUVEC cells in a high glucose environment and resist vascular injury caused by high glucose. The compound provided by the invention can increase the release amount of NO in HUVEC cells damaged by high glucose, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factors alpha.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of H2AC19 in the detection and treatment of lung adenocarcinoma. Specifically, this invention demonstrates that H2AC19 is abnormally highly expressed in lung adenocarcinoma patients, and this high expression is significantly associated with poor prognosis. Knockout of H2AC19 inhibits angiogenesis and tumor growth in vitro and in vivo, and reduces the proliferation, migration, and tube formation capabilities of lung adenocarcinoma cells in a co-culture model with human umbilical vein endothelial cells. Furthermore, this invention reveals a novel mechanism by which H2AC19 regulates angiogenesis through the p300 / EGR1 / MMP-1 pathway. This invention not only provides a superior method for the diagnosis and prognostic assessment of lung adenocarcinoma, but also lays an experimental foundation and expands new perspectives for the development of highly effective drugs for treating lung adenocarcinoma, thus possessing significant practical application value.

The invention discloses a method for promoting Notch1 protein expression through low-intensity pulse ultrasonic waves and an ultrasonic therapeutic apparatus, and belongs to the technical field of biology. The method comprises the following steps: inoculating third-generation human umbilical vein endothelial cells (HUVEC) on a 96-well plate coated with matrigel, culturing for 6 hours, and performing ultrasonic stimulation on the third-generation human umbilical vein endothelial cells by using low-intensity pulse ultrasonic waves with the intensity of 0.5-1.5 W / cm < 2 >, the pulse frequency of 1000Hz and the duty ratio of 50%. The method can effectively promote the protein expression of Notch1, thereby enhancing the tubulation ability of HUVEC cells. The ultrasonic therapeutic apparatus can emit ultrasonic waves with the intensity of 0.5-1.5 W / cm < 2 >, the pulse frequency of 1000Hz and the duty ratio of 50%, and the ultrasonic therapeutic apparatus can stimulate cells and promote protein expression of Notch1 in the cells, so that the tube forming capability of the cells is enhanced.

The application provides a nucleic acid molecule, a pro-angiogenic mesenchymal stromal cell and application thereof, relates to the biomedical technical field, and the nucleic acid molecule encodes HGF protein, or encodes VEGF165 protein and HGF protein; a first signal peptide is used as the signal peptide of the VEGF165 protein, and a second signal peptide is used as the signal peptide of the HGF protein. Through a gene modification strategy, MSC cells containing the nucleic acid molecule can stably and efficiently express VEGF165 and / or HGF, and the expression amount is significantly higher than that of MSC without the nucleic acid molecule. The cells have the ability to promote the migration of endothelial cells; meanwhile, the cells can also significantly promote the proliferation and tube formation of HUVEC cells, and further confirm the strong pro-angiogenic effect. The technical problem that nucleic acid molecules expressing VEGF165 or / HGF cannot be stably and efficiently expressed in the prior art is solved.

The invention provides a polypeptide-modified bacterial outer membrane vesicle and application thereof in preparation of a drug for promoting cell growth, and relates to the technical field of biological medicines. According to the invention, a growth promoting polypeptide VTPYGGGGVLLY with a brand new structure is designed on the basis of two micromolecular polypeptides VTPY and VLLY from sea cucumbers, and the engineering bacterial outer membrane vesicle W-VTPVLY OMV with a relatively strong growth promoting effect is prepared by combining the growth promoting polypeptide VTPYGGGGVLLY with bacterial outer membrane protein ClyA by utilizing a genetic engineering technology. The W-VTPVLY OMV provided by the invention has a remarkable promoting effect on HUVEC cell proliferation, migration and revascularization, can play a role in promoting cell proliferation within a short time, and can maintain the proliferation promoting effect for a relatively long time. The W-VTPVLY OMV provided by the invention is expected to become a new medicine for promoting wound regeneration and tissue healing, and provides a new thought and application reference for the fields of tissue engineering and medical materials.

The present invention relates to a pharmaceutical composition including an IL-32θ mutant for the prevention or treatment of inflammatory diseases and / or cancer and a use thereof. The interleukin-32θ mutant (IL-32θ mutant) of the present invention can inhibit inflammatory cytokines and chemokines, inflammatory mediators and the metastasis and proliferation of cancer through intracellular pathways, and can suppress the expression of Intracellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) in Human Umbilical Vein Endothelial Cells (HUVECs), and thus can be used for preventing and treating inflammatory diseases such as atherosclerosis through the inhibition of monocyte-endothelial cell adhesion. The mutant can also be utilized as a research material for various cancers and / or inflammatory diseases.

The application discloses a preparation method of bone organ-derived extracellular vesicles and application of the bone organ-derived extracellular vesicles in promoting angiogenesis. The application comprises the following steps: culturing bone marrow mesenchymal stem cells after osteogenic induction in a three-dimensional culture to construct bone organs, transfecting Hif-1 alpha plasmid, collecting bone organ culture supernatants of different culture time, separating and extracting extracellular vesicles through ultracentrifugation to obtain bone organ-derived extracellular vesicles (BOEVs) rich in BMP-2, TGF-beta 1, HIF-1 alpha and VEGF. The BOEVs are co-cultured with HUVEC cells, and the results show that the BOEVs can significantly promote the lumen formation and branching of the HUVEC cells by about 5 times, and up-regulate the expression of angiogenesis-related genes VEGF and CCN2, indicating that the BOEVs can promote angiogenesis.

Cryopreservation of endothelial cell monolayers is one of the major challenges in the cryopreservation of complex tissues. Human umbilical vein endothelial cells (HUVECs) in suspension are available commercially and recently their post-thaw cell membrane integrity was significantly improved by cryopreservation in 5% dimethyl sulfoxide (DMSO) and 6% hydroxyethyl starch (HES). However, cryopreservation of cells in monolayers has been elusive. The exact mechanisms of damage during cell monolayer cryopreservation are still under investigation. Here, we show that a combination of different factors contribute to significant progress in cryopreservation of cell monolayers. The addition of 2% chondroitin sulfate to 5% DMSO and 6% HES and cooling at 0.2 or 1° C. / min led to high membrane integrity (97.3±3.2%) immediately after thaw when HUVECs were cultured on a substrate with a coefficient of thermal expansion similar to that of ice. The optimized cryopreservation protocol was applied to monolayers of primary porcine corneal endothelial cells, and resulted in high post-thaw viability (95.9±3.7% membrane integrity) with metabolic activity 12 hours post-thaw comparable to unfrozen control.

The present invention discloses a ZIF-8-CeO2-miR200c nanozyme and a preparation method and application thereof. The present invention proposes for the first time that miR200c can reduce radiosensitivity and can prepare products for preventing and treating RISI, and provides a preparation method of a nanozyme containing miR200c: first prepare CeO2 nanoparticles, then add miR200c, 2-methylimidazole solution and zinc nitrate solution in sequence, and obtain a complex by sequential self-assembly; then encapsulate the above complex with C18PMH-PEG to synthesize ZIF-8-CeO2-miR200c. The ZIF-8-CeO2-miR200c nanozyme prepared by the present invention can promote the proliferation, migration, angiogenesis and anti-apoptosis ability of HaCaT and HUVEC cells, thereby exerting synergistic anti-radiation ability in vivo and in vitro. Provide an important reference for the biomaterial treatment of RISI.

The invention discloses application of avenanthramide D in preparation of a medicine for inhibiting angiogenesis, and relates to the technical field of biological medicine. Avenanthramide D is applied to intervene HUVEC cells, cell viability, cell apoptosis rate and angiogenesis ability after intervention are detected, and it is found that avenanthramide D can inhibit HUVEC cell proliferation, promote HUVEC cell apoptosis and inhibit HUVEC cell angiogenesis. A further experiment shows that the avenanthramide D reduces the integrity of an endothelial barrier by reducing the protein expression of a vascular endothelial growth factor A (VEGFA) and a platelet endothelial cell adhesion molecule 1 (CD31) in HUVEC cells, so that angiogenesis is blocked.

The present invention discloses a schizophyllan polysaccharide having two molecular weights of 1.54×10 7 Da and 1.85×10 4 The components of Da are composed of glucose, mannose, galactose, and fucose, with the molar ratio of glucose, mannose, galactose, and fucose being 86:8:5:1. The schizophyllan is a non-homopolymeric polysaccharide with glucose as its main component, which can promote the proliferation of HaCaT cells and HUVEC cells. At the same time, the schizophyllan can significantly accelerate the healing rate of wounds in mice with full-thickness skin wound models, and has excellent effects in epithelial re-formation, granulation tissue formation, and tissue remodeling. When 4 mg / mL of schizophyllan is used to treat mouse wounds, the healing rate reaches 96.65%.